Cargando…

The Emergence of Hybrid Variants of SARS-CoV-2: Towards Hybrid Immunity

Detalles Bibliográficos
Autores principales:	Chavda, Vivek P., Vuppu, Suneetha, Mishra, Toshika, Balar, Pankti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144432/ https://www.ncbi.nlm.nih.gov/pubmed/37112676 http://dx.doi.org/10.3390/vaccines11040764

Ejemplares similares

Immunological Studies to Understand Hybrid/Recombinant Variants of SARS-CoV-2
por: Chavda, Vivek P., et al.
Publicado: (2022)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
por: Teli, Divya, et al.
Publicado: (2023)

Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management
por: Chavda, Vivek P., et al.
Publicado: (2023)

Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants
por: Chavda, Vivek P., et al.
Publicado: (2023)

Recent review of COVID-19 management: diagnosis, treatment and vaccination
por: Chavda, Vivek P., et al.
Publicado: (2022)

Post-COVID-19 Fungal Infection in the Aged Population
por: Chavda, Vivek P., et al.
Publicado: (2023)

Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population
por: Chavda, Vivek P., et al.
Publicado: (2023)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?
por: Chavda, Vivek P, et al.
Publicado: (2022)

Current status of Cancer Nanotheranostics: Emerging strategies for cancer management
por: Chavda, Vivek P, et al.
Publicado: (2023)

Hybrid SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2022)

Nanotheranostics-based Management of Head and Neck Cancer
por: Chavda, Vivek P., et al.
Publicado: (2023)

Interventional nanotheranostics in hepatocellular carcinoma
por: Chavda, Vivek P., et al.
Publicado: (2023)

SARS-CoV-2: Immunopeptidomics and Other Immunological Studies
por: Chavda, Vivek P., et al.
Publicado: (2022)

A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals
por: Chavda, Vivek P, et al.
Publicado: (2021)

The emergence, dynamics and significance of SARS-CoV-2 variants
por: COLSON, Philippe, et al.
Publicado: (2022)

Emerging SARS-CoV-2 variants: shooting the messenger
por: The Lancet Infectious Diseases
Publicado: (2022)

Propolis and Their Active Constituents for Chronic Diseases
por: Chavda, Vivek P., et al.
Publicado: (2023)

Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants
por: Andreano, Emanuele, et al.
Publicado: (2021)

Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
por: Chavda, Vivek P., et al.
Publicado: (2022)

SARS-CoV-2: from herd immunity to hybrid immunity
por: Goldblatt, David
Publicado: (2022)

Implications of the Emerging SARS-CoV-2 Variant: Caution is the Key
por: Al Awaidy, Salah T., et al.
Publicado: (2021)

New emerging SARS-CoV-2 variants and antiviral agents
por: Vitiello, A., et al.
Publicado: (2023)

Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS‐CoV‐2 in the endemic phase?
por: Pilz, Stefan, et al.
Publicado: (2022)

Antibody–Biopolymer Conjugates in Oncology: A Review
por: Chavda, Vivek P., et al.
Publicado: (2023)

Multivalent vaccines against new SARS-CoV-2 hybrid variants
por: Ghazvini, Kiarash, et al.
Publicado: (2023)

Multivalent vaccines against new SARS-CoV-2 hybrid variants
por: Ghazvini, Kiarash, et al.
Publicado: (2023)

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
por: Goldberg, Yair, et al.
Publicado: (2022)

Complementarity determining regions in SARS-CoV-2 hybrid immunity
por: Frans, Glynis, et al.
Publicado: (2023)

An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants
por: Bates, Timothy A., et al.
Publicado: (2023)

How Antivirals Might be Linked to the Emergence of New Variants of SARS-CoV-2
por: Mehdizadeh, Ali Reza, et al.
Publicado: (2021)

Emerging, hybrid & smart composites
por: Binetruy, Christophe, et al.
Publicado: (2021)

Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein
por: den Hartog, Gerco, et al.
Publicado: (2023)

The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants
por: Choi, Hosoon, et al.
Publicado: (2021)

SARS-CoV-2 hybrid immunity: silver bullet or silver lining?
por: Suryawanshi, Rahul, et al.
Publicado: (2022)

Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients
por: Kared, Hassen, et al.
Publicado: (2023)

Characterisation of pectin and optimization of pectinase enzyme from novel Streptomyces fumigatiscleroticus VIT-SP4 for drug delivery and concrete crack-healing applications: An eco-friendly approach
por: Govindaraji, Praveen Kumar, et al.
Publicado: (2020)

The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
por: Chavda, Vivek P., et al.
Publicado: (2022)

Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants
por: Cegolon, Luca, et al.
Publicado: (2023)

Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants
por: Jain, Sankalp, et al.
Publicado: (2021)

Organic–Inorganic Hybrid Nanocomposites for Nanotheranostics: Special Focus on Preventing Emerging Variants of SARS-COV-2
por: Mukherjee, Sayan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tom343s8rq8c4ctc6e1jj1e6kl